Puma Biotechnology Inc (PBYI)
5.07
+0.19
(+3.89%)
USD |
NASDAQ |
Apr 26, 12:32
Puma Biotechnology Gross Profit Margin (Quarterly): 66.30% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 66.30% |
| September 30, 2023 | 76.33% |
| June 30, 2023 | 78.27% |
| March 31, 2023 | 74.95% |
| December 31, 2022 | 74.36% |
| September 30, 2022 | 78.12% |
| June 30, 2022 | 74.94% |
| March 31, 2022 | 76.29% |
| December 31, 2021 | 78.51% |
| September 30, 2021 | 77.77% |
| June 30, 2021 | 77.58% |
| March 31, 2021 | 69.89% |
| December 31, 2020 | 79.18% |
| Date | Value |
|---|---|
| September 30, 2020 | 80.41% |
| June 30, 2020 | 86.66% |
| March 31, 2020 | 82.28% |
| December 31, 2019 | 83.88% |
| September 30, 2019 | 83.37% |
| June 30, 2019 | 82.72% |
| March 31, 2019 | 91.94% |
| December 31, 2018 | 85.43% |
| September 30, 2018 | 85.55% |
| June 30, 2018 | 82.60% |
| March 31, 2018 | 90.40% |
| December 31, 2017 | 81.28% |
| September 30, 2017 | 74.89% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
66.30%
Minimum
Dec 2023
86.66%
Maximum
Jun 2020
77.99%
Average
78.12%
Median
Sep 2022
Gross Profit Margin (Quarterly) Benchmarks
| ADMA Biologics Inc | 42.06% |
| Regeneron Pharmaceuticals Inc | 84.95% |
| Sarepta Therapeutics Inc | 88.87% |
| CytomX Therapeutics Inc | -- |
| Mirum Pharmaceuticals Inc | 64.03% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 63.49% |
| Return on Assets | 10.25% |
| Return on Invested Capital | 16.24% |
| Profit Margin (Quarterly) | 17.00% |
| Operating Margin (Quarterly) | 20.50% |
| Return on Net Operating Assets | 17.72% |